The primary target of Desonide is the cytoplasmic glucocorticoid receptor. As an agonist, this compound diffuses across the cell membrane and binds to the glucocorticoid receptor. The activated receptor complex then translocates to the nucleus, modulating the transcription of various anti-inflammatory protein genes. Its specific mechanism involves inducing the synthesis of phospholipase A2 inhibitory proteins (collectively called lipocortins), which control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. This multi-level anti-inflammatory action forms the basis for its efficacy in treating cutaneous inflammatory disorders.

In vitro studies demonstrate that Desonide acts as a glucocorticoid receptor agonist to exert its anti-inflammatory effects. At the cellular level, the compound inhibits phospholipase A2 activity by inducing lipocortin synthesis, thereby blocking the release of arachidonic acid and reducing the production of prostaglandins and leukotrienes. Desonide is a low-potency topical corticosteroid, and its activity is typically assessed using the vasoconstrictor assay (skin blanching test), which has been established as a surrogate method for evaluating the bioequivalence of topical corticosteroids. Classic in vitro methods also include evaluating the compound's inhibitory effect on the production of inflammation-related cytokines such as IL-1, IL-6, and TNF-α.

In vivo studies confirm the efficacy of Desonide in various models of inflammation and allergy. In animal models, the compound reduces cantharidin-induced non-immune inflammation and delayed hypersensitivity reactions in the mouse ear. Human studies show that Desonide ointment/cream (0.05%) is effective in treating atopic dermatitis and eczema, placing it in the low-potency range. When applied to large body surface areas (e.g., 30%) under occlusion for one week, HPA axis suppression may occur in approximately 1 in 10 patients. The vasoconstrictor assay is used to assess bioequivalence, and a study in a Chinese population showed no significant difference between the test and reference formulations.

Cell-free assays for Desonide primarily focus on its binding affinity to the glucocorticoid receptor. A typical protocol includes: 1) Prepare cell lysates expressing human glucocorticoid receptor or use recombinant receptor protein; 2) Dissolve Desonide in DMSO and dilute with binding buffer (containing 10 mM Tris-HCl pH 7.4, 10% glycerol, 1 mM DTT) to serial concentrations (0.1 nM - 10 μM); 3) Add radiolabeled ligand (e.g., [³H]-dexamethasone at a final concentration of approximately 5-10 nM); 4) Incubate overnight (12-16 hours) at 4°C; 5) Add dextran-coated charcoal solution to separate bound and free ligands, centrifuge, and collect supernatant; 6) Measure radioactivity using a liquid scintillation counter and calculate IC₅₀ and Ki values from competition binding curves.

The in vitro cell assay protocol for Desonide is as follows for evaluating anti-inflammatory activity: 1) Culture target cells (such as human dermal fibroblasts, keratinocytes, or macrophages) in medium containing 10% FBS at 37°C with 5% CO₂ until logarithmic growth phase; 2) Seed cells in multi-well plates (approximately 1×10⁵ cells per well) and culture overnight for cell attachment; 3) Pre-treat cells with various concentrations of Desonide (typically 0.001 - 10 μM) for 1-2 hours; 4) Add inflammatory stimuli (e.g., lipopolysaccharide 1 μg/mL or TNF-α 10 ng/mL) to activate cells; 5) Continue incubation for 6-24 hours; 6) Collect cell supernatants and measure levels of inflammatory cytokines (IL-6, IL-8, TNF-α, PGE2) by ELISA; 7) Collect cell lysates and detect expression of proteins such as COX-2 and iNOS by Western blot; 8) Calculate IC₅₀ values to evaluate anti-inflammatory potency.

In vivo animal assays for Desonide commonly employ the following classic models to evaluate anti-inflammatory and anti-allergic activities: 1) Use 6-8 week old male BALB/c mice or SD rats; 2) Acute inflammation model: induce ear edema by topical application of croton oil or phorbol ester (TPA) to the mouse ear, apply Desonide (0.01%-0.1%) topically before or after inflammation induction; 3) Chronic inflammation model: use an atopic dermatitis-like mouse model (e.g., calcipotriol-induced or MC903-induced), apply Desonide ointment topically for 7-14 consecutive days; 4) Allergic contact dermatitis model: sensitize and challenge with picryl chloride or DNFB, assess ear swelling and histopathological changes; 5) At study termination, euthanize animals, collect ear punches for weighing to calculate swelling inhibition rate, and collect skin tissue for histopathological examination (H&E staining, toluidine blue staining); 6) Measure inflammatory cytokine levels and MPO activity in skin tissue.

Absorption, Distribution and Excretion
Topical corticosteroids can be absorbed from normal, intact skin. Skin inflammation and/or other disease processes may increase transdermal absorption.

---

The pharmacokinetic profile of Desonide primarily involves percutaneous absorption and systemic distribution. The extent of percutaneous absorption after topical application is determined by multiple factors, including the vehicle, skin barrier integrity, application site, and use of occlusive dressings. Absorption through healthy intact skin is limited, but skin inflammation or compromised epidermal barrier may increase percutaneous absorption. Desonide is a low-potency corticosteroid with relatively low percutaneous absorption. Human pharmacokinetic studies show that after a single application of 0.05% Desonide cream, the peak concentration (Cmax) is approximately 20 pg/mL, and AUC0-t is approximately 450 pg·h/mL. Like other corticosteroids, Desonide is metabolized in the liver, primarily to 6β-hydroxy-desonide and 16α-hydroxyprednisolone, which are 50-100 times less potent than the parent steroid.

Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation
Desonide has not been studied during lactation. Since only large-area application of potent corticosteroids is likely to have systemic effects on the mother, short-term topical application of corticosteroids is unlikely to pose a risk to the nursing infant through breast milk. However, it is a precaution to use the least potent medication on the smallest possible area of skin. It is especially important to ensure that the infant's skin does not come into direct contact with the treated area. Water-soluble creams or gels should only be applied to the breasts, as ointments may expose the infant to high concentrations of mineral oil through licking. Desonide cream or foam can be used on the nipples. If topical corticosteroids are applied to the breast or nipple area, they should be thoroughly wiped off before breastfeeding.
◉ Effects on Breastfed Infants
A mother applied a topical corticosteroid (isofluprednisolone acetate) with high mineralocorticoid activity to her nipples, resulting in QT interval prolongation, Cushing's syndrome-like symptoms, severe hypertension, growth retardation, and electrolyte imbalance in her 2-month-old breastfed infant. The mother had been using the cream due to nipple pain since the infant's birth.
◉ Effects on Lactation and Breast Milk
As of the revision date, no relevant published information was found.

---

As a low-potency topical corticosteroid, Desonide is generally well-tolerated with low risk of systemic toxicity when used as directed. However, systemic toxicity may occur with long-term or extensive use, primarily manifesting as reversible hypothalamic-pituitary-adrenal (HPA) axis suppression. Clinical studies show that when applied to approximately 30% of body surface area under occlusion for one week, HPA axis suppression occurs in about 1 in 10 patients. Systemic absorption may produce manifestations of Cushing‘s syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface area to body mass ratios. Local adverse effects include application site irritation and allergic contact dermatitis (rare). If concomitant skin infections develop, use of Desonide should be discontinued until the infection has been adequately controlled.

[1]. Expert Opin Investig Drugs.2008 Jul;17(7):1097-104;
[2]. J Drugs Dermatol.2010Apr;9(4):324-9.

Desonide is a triamcinolone acetone derivative, with the fluorine substituent at position 9 replaced by a hydrogen atom. It is a corticosteroid anti-inflammatory drug, applied topically as a cream, ointment, or lotion to treat various skin conditions. It has anti-inflammatory effects. It is an 11β-hydroxysteroid, 21-hydroxysteroid, 20-oxosteroid, corticosteroid, cyclic ketal, 3-oxo-Δ⁹Δ⁴-steroid, and primary α-hydroxyketone.
A non-fluorinated corticosteroid anti-inflammatory drug, used topically to treat skin diseases.
Desonide is a corticosteroid. The mechanism of action of desonide is as a corticosteroid hormone receptor agonist.
Desonide is a synthetic glucocorticoid used topically with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is transported to the nucleus as a homodimer, where the glucocorticoid response element activates the transcription of glucocorticoid response genes. This drug induces the transcription of genes encoding anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonists, and neutral endopeptidase. Increased lipocortin-1 synthesis inhibits phospholipase A2, thereby inhibiting the release of arachidonic acid and controlling the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes.
A non-fluorinated corticosteroid anti-inflammatory drug used to treat skin diseases.
See also: desonide sodium phosphate (its active ingredient); glacial acetic acid; desonide (one of the components).
Indications
For the relief of inflammatory and pruritus symptoms in corticosteroid-responsive dermatitis.
Mechanism of Action
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive effects. The drug binds to cytoplasmic glucocorticoid receptors. This complex migrates to the cell nucleus and binds to genetic elements on DNA. This activates and inhibits various genes. However, it is believed that the mechanism of action of corticosteroids is through inducing the production of phospholipase A2-inhibiting proteins (collectively known as lipocortin). These proteins are presumed to control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Desolide is a synthetic, non-fluorinated corticosteroid used for topical dermatological treatment. Corticosteroids are a class of steroids primarily composed of synthetic compounds, used topically as anti-inflammatory and antipruritic agents.

C24H32O6

416.51

416.219

C, 69.21; H, 7.74; O, 23.05

638-94-8

5311066

White to off-white solid powder

1.3±0.1 g/cm3

580.1±50.0 °C at 760 mmHg

274 - 275ºC

196.9±23.6 °C

0.0±3.7 mmHg at 25°C

1.598

2.62

2

6

2

30

873

8

C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O

WBGKWQHBNHJJPZ-QHDHGWJCSA-N

InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15?,16?,17-,19+,20?,22-,23-,24+/m0/s1

(6aR,7S,8aS,8bS,11aR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one

DESONIDE; 638-94-8; Topifug; Sterax; Prednacinolone; Steroderm; Apolar; D 2083; D2083; D-2083; Locapred; Budesonide acetonide; Prenacid; Tridesonit; Prednisolone acetonide; Desowen;DesOwen; Desonida;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

Solubility in Formulation 4: 2% DMSO +49%PEG 300 +dd H2O: 10mg/mL

---

 (Please use freshly prepared in vivo formulations for optimal results.)